Targeting the KLF5/PI3K/AKT axis as a therapeutic strategy to overcome neoadjuvant chemoresistance in colorectal cancer
BackgroundOxaliplatin-based neoadjuvant chemotherapy (NAC) is the standard treatment for advanced colorectal cancer (CRC), yet resistance to NAC poses a significant clinical challenge.MethodsTo investigate the mechanisms of chemoresistance, we analyzed single-cell RNA sequencing (scRNA-seq) data fro...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1593639/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | BackgroundOxaliplatin-based neoadjuvant chemotherapy (NAC) is the standard treatment for advanced colorectal cancer (CRC), yet resistance to NAC poses a significant clinical challenge.MethodsTo investigate the mechanisms of chemoresistance, we analyzed single-cell RNA sequencing (scRNA-seq) data from CRC patients undergoing NAC. Comprehensive analyses, including InferCNV, differentially expressed genes analysis, pathway enrichment, cell communication, and SCENIC were performed. High-throughput drug screening identified potential therapeutic candidates targeting chemoresistance pathways, and the efficacy of targeting the KLF5/PI3K/AKT axis in combination with oxaliplatin was explored in animal models.ResultsNAC effectively reduced tumor burden and enhanced T_NK cell infiltration in responsive tumors. Notably, NAC-resistant cell clusters exhibited activation of fatty acid-related metabolic pathways and demonstrated limited immune infiltration. Transcriptional analysis identified KLF5 as a potential driver of chemotherapy resistance. Based on these findings, we developed a KLF5 regulon-associated risk score model with significant potential for predicting CRC patient prognosis. Mechanistically, KLF5 activation of the PI3K/AKT pathway conferred chemoresistance in CRC cells. Through high-throughput screening, GDC-0941, a PI3K/AKT inhibitor, emerged as a promising therapeutic agent that synergistically enhanced oxaliplatin efficacy and overcame resistance in preclinical models.ConclusionsTargeting the KLF5/PI3K/AKT axis may enhance chemotherapy efficacy and overcome drug resistance in CRC. |
|---|---|
| ISSN: | 1664-3224 |